SummarySystematic studies of cancer genomes have provided unprecedented insights into the molecular nature of cancer. Using this information to guide the development and application of therapies in the clinic is challenging. Here, we report how cancer-driven alterations identified in 11,289 tumors from 29 tissues (integrating somatic mutations, copy number alterations, DNA methylation, and gene expression) can be mapped onto 1,001 molecularly annotated human cancer cell lines and correlated with sensitivity to 265 drugs. We find that cell lines faithfully recapitulate oncogenic alterations identified in tumors, find that many of these associate with drug sensitivity/resistance, and highlight the importance of tissue lineage in mediating dru...
One approach to identifying cancer-specific vulnerabilities and therapeutic targets is to profile ge...
Genome sequencing of tumors provides a wealth of information on mutations and structural variations,...
Pharmacogenomics in oncology holds the promise to personalize cancer therapy. However, its clinical ...
Systematic studies of cancer genomes have provided unprecedented insights into the molecular nature ...
Systematic studies of cancer genomes have provided unprecedented insights into the molecular nature ...
SummarySystematic studies of cancer genomes have provided unprecedented insights into the molecular ...
Summary Systematic studies of cancer genomes have provided unprecedented insights into the molecular...
Over the last decade we have witnessed the convergence of two powerful experimental designs toward a...
One of the most challenging problems in the development of new anticancer drugs is the very high att...
of anticancer drug sensitivity A full list of authors and affiliations appears at the end of the art...
Clinical responses to anticancer therapies are often restricted to a subset of patients. In some cas...
The systematic translation of cancer genomic data into knowledge of tumour biology and therapeutic p...
Clinical responses to anticancer therapies are often restricted to a subset of patients. In some cas...
SummaryThe high rate of clinical response to protein-kinase-targeting drugs matched to cancer patien...
One approach to identifying cancer-specific vulnerabilities and therapeutic targets is to profile g...
One approach to identifying cancer-specific vulnerabilities and therapeutic targets is to profile ge...
Genome sequencing of tumors provides a wealth of information on mutations and structural variations,...
Pharmacogenomics in oncology holds the promise to personalize cancer therapy. However, its clinical ...
Systematic studies of cancer genomes have provided unprecedented insights into the molecular nature ...
Systematic studies of cancer genomes have provided unprecedented insights into the molecular nature ...
SummarySystematic studies of cancer genomes have provided unprecedented insights into the molecular ...
Summary Systematic studies of cancer genomes have provided unprecedented insights into the molecular...
Over the last decade we have witnessed the convergence of two powerful experimental designs toward a...
One of the most challenging problems in the development of new anticancer drugs is the very high att...
of anticancer drug sensitivity A full list of authors and affiliations appears at the end of the art...
Clinical responses to anticancer therapies are often restricted to a subset of patients. In some cas...
The systematic translation of cancer genomic data into knowledge of tumour biology and therapeutic p...
Clinical responses to anticancer therapies are often restricted to a subset of patients. In some cas...
SummaryThe high rate of clinical response to protein-kinase-targeting drugs matched to cancer patien...
One approach to identifying cancer-specific vulnerabilities and therapeutic targets is to profile g...
One approach to identifying cancer-specific vulnerabilities and therapeutic targets is to profile ge...
Genome sequencing of tumors provides a wealth of information on mutations and structural variations,...
Pharmacogenomics in oncology holds the promise to personalize cancer therapy. However, its clinical ...